EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

BeOne Medicines AG (6160) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of BeOne Medicines AG HK$170, price HK$215, upside -21.1%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · HK · ISIN KYG1146Y1017

BM Some data Sep 24, 2026

BeOne Medicines AG

6160 · HK

Overvalued / MonitorQuality growthQuality is not strong enough to offset the price risk.

!Fair value HK$169.72 · Overvalued (−21%)
✓Quality 70/100
!Mixed Growth (revenue 5y +76.9 %/yr)
!Thin margins · 8.9% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (7/13)
!Moderate moat 57/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 5 out of 100
Watch BeOne Medicines AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$278.60 HK$74.35 Fair Value HK$169.72 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range HK$74.35 – HK$278.60 · fair‑value band HK$118.82 – HK$220.64 · the HK$215.20 price screens above the HK$169.72 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow BeOne Medicines in your weekly email

Every Wednesday you see whether BeOne Medicines is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

Show more

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Stock analysis

BeOne Medicines AG (6160) currently trades at HK$215.20, while our model-based Fair Value estimate is HK$169.72, implying the stock looks roughly 26.8% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 24 models at a data quality of 94/100, which puts the evidence level at medium.

Scenario range: HK$118.82 (bear) to HK$220.64 (bull), the price of HK$215.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BeOne Medicines AG reported revenue of $5.4B in FY2025 versus $1.2B in FY2021, a compound +46.0%/yr. Reported net income was $287M in FY2025.

Key figures

Market cap HK$317B (≈ $40.5B) · P/E ratio 65.7 · P/S ratio 3.53 · EPS (TTM) HK$2.73 · Net margin 5.4% · Return on equity 12.4% · Return on assets (EBIT) −13.9% · Operating margin 16.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).

What moves the price

Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.

The share trades about 6% below its 52-week high and 38% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −21%, 6160 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (HK$2.37 to HK$28.01). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear HK$118.82 Fair Value HK$169.72 Bull HK$220.64
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$2.00 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF HK$16.37 HK$24.07 HK$48.60 74
EPV HK$5.39 HK$5.80 HK$6.16 74
Growth DCF HK$15.57 HK$28.01 HK$48.40 73
All 24 models by family
DCF Models
FCF DCF HK$16.37 HK$24.07 HK$48.60 74
Owner Earnings HK$6.56 HK$11.18 HK$20.87 71
5Y Revenue Exit HK$9.29 HK$12.68 HK$19.66 70
5Y EBITDA Exit HK$10.41 HK$14.94 HK$23.77 72
5Y P/E Exit HK$9.52 HK$15.42 HK$23.09 68
10Y Revenue Exit HK$11.31 HK$18.40 HK$22.00 66
10Y EBITDA Exit HK$12.27 HK$20.81 HK$34.75 64
10Y P/E Exit HK$11.62 HK$18.89 HK$29.96 61
Earnings-Based
Graham-Dodd HK$1.58 HK$11.05 HK$15.50 61
Lynch FV HK$5.71 HK$8.15 HK$10.60 59
PEG = 1.0 HK$5.71 HK$8.15 HK$10.60 55
EPV HK$5.39 HK$5.80 HK$6.16 74
Multiples
P/E Multiple HK$3.84 HK$5.12 HK$6.41 63
P/S Multiple HK$2.97 HK$3.96 HK$4.95 58
P/B Multiple HK$2.97 HK$3.96 HK$4.95 55
EV/EBIT HK$7.57 HK$9.11 HK$10.65 66
EV/EBITDA HK$7.96 HK$9.63 HK$11.30 67
EV/Revenue HK$6.24 HK$7.66 HK$9.07 54
Asset-Based
NCAV (Graham) HK$1.77 HK$2.37 HK$3.53 54
Growth DCF
Growth DCF HK$15.57 HK$28.01 HK$48.40 73
Rev-Margin DCF HK$9.87 HK$14.10 HK$23.04 69
Economic Profit
Residual Income HK$2.83 HK$2.96 HK$3.10 68
ROIC Compounder HK$6.09 HK$7.69 HK$9.80 70
Growth Earnings
Growth-Adj P/E HK$7.58 HK$10.82 HK$14.07 65

Open the full fair value analysis →

Notify me when 6160 reaches fair value

Put 6160 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 70/100

Of which business quality 70 · Market factors (momentum, volatility) 70

Profitability 49
Margins and returns on capital today
Quality Growth 82
Are margins and returns improving?
Cashflow 83
Earnings quality: real cash, not paper profit
Fin. Strength 93
Balance sheet, leverage, solvency risk
Investment 83
Disciplined investing over empire-building
Low Volatility 75
Calm price path (market factor)
Momentum 71
Price trend over the last 3–12 months (market factor)
52W Momentum 62
Distance to the 52-week high (market factor)
Net Issuance 26
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 87/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+40.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+55.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.9%
Start year 2020 (pandemic). Over 10 years: +89.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+67.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−536.7% (2020) → 8.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+14.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +15.9% a year for the price and +11.3% for the forecasts.
Forecast 2026 (sales)+20.9%
Forecast 2027 (sales)+14.7%
Projected 2028 (sales)+13.1%
Projected 2029 (sales)+11.5%
Projected 2030 (sales)+9.9%

6160 screens 27% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare BeOne Medicines AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside −21% · Above median
Profitability
Return on equity (TTM) 12% · Top 25%
Return on assets 6% · Top 25%
Net margin (TTM) 9% · Above median
Operating margin (TTM) 17% · Top 25%
Growth and dividend
Revenue growth 36% · Top 25%
Balance sheet
Debt / equity 0.22× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 65.7× · Priciest 25%
P/B 9.28× · Priciest 25%
P/S (TTM) 7.05× · Pricier than median
P/FCF 42.9× · Priciest 25%
EV/EBITDA 44.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)50 · sector 0
HEALTH (low debt)89 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%
Incyte Corporation INCY $124.64 $205.18 +65%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BeOne Medicines AG · Fair Value
HK$169.72 −27%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "BeOne Medicines AG Fair Value". https://www.fairvalue-calculator.com/stock/6160

Frequently asked questions

Is BeOne Medicines AG (6160) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$169.72 versus a price of HK$215.20, about −21% upside (overvalued).
What is the fair value of 6160?
Our model-based fair value for BeOne Medicines AG is HK$169.72 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$215.20.
What is the quality score of 6160?
BeOne Medicines AG has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BeOne Medicines AG (6160)?
Our model-based price target is the fair value of HK$169.72 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario HK$118.82, optimistic scenario HK$220.64. It is a calculation from audited fundamentals, not an analyst target.
What is the BeOne Medicines AG stock forecast for 2026?
Our models put fair value at HK$169.72, about −21% upside versus a price of HK$215.20 (overvalued). Cautious scenario HK$118.82, optimistic scenario HK$220.64. The calculation is refreshed regularly with new filings.
What is the revenue of BeOne Medicines AG (6160)?
BeOne Medicines AG reported trailing-twelve-month revenue of about $5.7B (latest available figure, as of Sep 24, 2026).
What growth is priced into BeOne Medicines AG (6160)?
For today's price to be fair in a discounted-cash-flow model, BeOne Medicines AG would have to grow free cash flow by +18.6 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +76.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 6160 use?
Our models discount BeOne Medicines AG at 8.6 %: a base by market capitalisation (large), damped by beta 0.49, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BeOne Medicines AG that is +18.6 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has BeOne Medicines AG (6160) delivered so far?
Over the past 5 years revenue at BeOne Medicines AG grew +76.9 % a year. The price currently implies +18.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BeOne Medicines AG (6160) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into BeOne Medicines AG (+18.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BeOne Medicines AG (6160)?
The free-cash-flow yield on the price is 2.33 %: that much free cash flow BeOne Medicines AG produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BeOne Medicines AG (6160)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BeOne Medicines AG it is HK$169.72 per share (as of Sep 24, 2026), against a price of HK$215.20. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is BeOne Medicines AG stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6160 trades above its calculated fair value: price HK$215.20, fair value HK$169.72, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6160?
No. The price is what the market pays today (HK$215.20); the fair value is what the company's own numbers justify (HK$169.72). For BeOne Medicines AG the two are HK$45.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is BeOne Medicines AG worth?
The market values BeOne Medicines AG at about HK$317B (market capitalisation, as of Sep 24, 2026). Per share that is HK$215.20; our models calculate a fair value of HK$169.72 per share.
What do the bullish and bearish scenarios say about 6160?
Our models span a range for BeOne Medicines AG: cautious scenario HK$118.82, base HK$169.72, optimistic HK$220.64 per share (as of Sep 24, 2026, price HK$215.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6160?
BeOne Medicines AG trades at a price-to-earnings ratio of 65.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$169.72 is built from several models across several years. Other multiples: P/B 9.3, P/S 7.1, EV/EBITDA 44.6.
How solid is the balance sheet of BeOne Medicines AG (6160)?
Balance-sheet figures for BeOne Medicines AG (as of Sep 24, 2026): return on equity 12.4%, debt of 0.22 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 6160 from its 52-week high?
BeOne Medicines AG trades at HK$215.20, about 6% below its 52-week high of HK$229.00 and 38% above the low of HK$155.40 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$169.72 is for.
Which stocks are comparable to BeOne Medicines AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BeOne Medicines AG stock attractive at the current price?
The data as of Sep 24, 2026: price HK$215.20, calculated fair value HK$169.72 (−21%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6160 calculated?
We run BeOne Medicines AG through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$169.72, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. BeOne Medicines AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BeOne Medicines AG (6160)?
The closing price on Sep 24, 2026 was HK$215.20. Our model-based fair value is HK$169.72, about −21% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BeOne Medicines AG right now?
A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range (HK$118.82 to HK$220.64) leaves room in how you read the outcome.

Key figures of BeOne Medicines AG

How large is the market capitalisation of BeOne Medicines AG (6160)?
The market capitalisation of BeOne Medicines AG is HK$317B (≈ $40.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BeOne Medicines AG (6160)?
The price-to-sales ratio of BeOne Medicines AG is 3.53 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BeOne Medicines AG (6160)?
Earnings per share at BeOne Medicines AG are HK$2.73 (price ÷ EPS = P/E 65.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BeOne Medicines AG (6160)?
The net margin of BeOne Medicines AG is 5.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BeOne Medicines AG (6160)?
The return on equity (ROE) of BeOne Medicines AG is 12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BeOne Medicines AG (6160)?
On an EBIT basis the return on assets of BeOne Medicines AG is −13.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BeOne Medicines AG (6160)?
The operating margin of BeOne Medicines AG is 16.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BeOne Medicines AG (6160)?
Revenue at BeOne Medicines AG is growing +35.5% versus a year earlier (3y avg +55.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BeOne Medicines AG (6160)?
Earnings per share at BeOne Medicines AG are growing +170% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does BeOne Medicines AG (6160) hold?
BeOne Medicines AG holds more cash than debt, $3.5B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BeOne Medicines AG in the live analysis

One click puts BeOne Medicines AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.